senrex,
re: the work being unique, you nailed it when you said-
..."probably looking at the "mab" part of "Bavituximab"...
It depends on how closely you look at the work.
In general terms of targeted therapy with mabs against cancer, there are obviously others.
More specifically, in terms of companies pursuing mabs to phospholipids as treatments to cancers, or viral infections, the "work is unique"
Targeting aminophospholipids (like PS), deliberately, (which would have sounded nuts to most any immunologist just 10 yrs ago), is all Peregrine.
The closest other related work I'm aware of, is the CHAVI 005 protocol, (Bart Haynes), which may be studying mabs that target a phospholipid, originally isolated from people with autoimmune diseases.
There's also some work at The Walter Reed Institute, (Carl Alving), which is looking into neutralizing HIV via mabs targeting phosphatidylinositol phosphate, (PIP).
(both of those I've posted about quite a bit here on Ihub).
Peregrine's work using mabs to PS, and especially being all alone in human trials targeting PS, (let alone now in phase 2 cancer trials), is unique.
Even speaking more generally, the idea of targeted therapy for cancer or viruses through targeting something that is NOT a cancer or viral antigen, is a concept that is still early in the curve of catching on.
j
News 
Market Data 
Discover 
AI
